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Strategies that enable E1-defective recombinant adenoviruses to selectively undergo replication in neoplastic tissue may
be useful for future investigations or therapies of malignancies. A growing body of evidence suggests that some molecular
alterations commonly associated with malignancies, such as p53 mutations, can modify the specific E1 requirements for
replication of human serotype adenoviruses. In the studies reported here, a panel of human non-small cell lung cancer cell
lines with previously defined p53 status were characterized for basal interleukin-6 (IL-6) and bcl-2 content because previous
studies have indicated both proteins can functionally substitute for the replication requirements provided by native E1 viral
proteins. Cell lines were infected with E1-defective adenovirus 5 and simultaneously transfected with different combinations
of E1 plasmids, or a bcl-2 expression plasmid, and adenovirus present in the cells was quantified 6 days later. These assays
demonstrated that E1A with both 19- and 55-kDa E1B-encoding plasmids were required for maximal adenoviral replication,
independent of the varying p53/IL-6/basal bcl-2 phenotypes of the host cell lines. E1A was required for maximal replication
enablement, independent of the basal IL-6 content of these cell lines, and exogenous IL-6 also did not obviate the E1A
requirement. Interestingly, the bcl-2 expression plasmid did not consistently substitute for the 19-kDa expression plasmid in
the context of this replication complementation assay. These results suggest that (1) basal levels of IL-6 greater than that
present in these cell lines are necessary for functional replacement of the E1A replication function and (2) bcl-2 does not
predictably substitute for the 19-kDa E1B replication function in the context of trans complementation. © 1998 Academic Press
INTRODUCTION
Adenoviruses have emerged as leading vectors for the
transfer of ‘‘therapeutic’’ genes to neoplastic cells. Ad-
vantages include the high titer, lack of integration, and
the easily manipulated genome that can incorporate the
size of most therapeutic genes with readily available
shuttle vectors (as recently reviewed in Curiel and
Garver, 1997). The prototypical recombinant adenovirus
under investigation for cancer gene therapy has both the
E1A and E1B units deleted and replaced by a therapeutic
gene. The E1 deletion generally renders the virus repli-
cation-defective (Harrison et al., 1977; Jones and Shenk,
1979a,b), although low levels of viral replication can
occur under specific conditions such as high multiplici-
ties of infection (Shenk et al., 1979; Carlock and Jones,
1981; Nevins, 1981; Gaynor and Berk, 1983).
Although conventional E1-defective adenoviral vectors
were intentionally designed to be replication-defective,
selective adenoviral replication within neoplastic tissues
may be advantageous in two ways. First, selective rep-
lication of a recombinant adenovirus containing a thera-
peutic gene might be expected to amplify adenoviral
spread within a tumor, resulting in amplified expression
of the transgene. The potential value of this strategy has
been addressed in prior reports from this lab showing
that selective replication-enablement of E1-defective ad-
enovirus did amplify viral transgene expression and ther-
apeutic effect in animal tumor models (Goldsmith et al.,
1994; Dion et al., 1996a,b). Second, cell lysis resulting
from productive adenoviral replication might be exploited
as a cytoreductive strategy for cancer treatment if the
replication could be selectively activated within the neo-
plastic tissues. The possible utility of this cytoreductive
approach has been used to reduce engrafted carcinoma
cell line tumor nodule size in mice (Bischoff et al., 1996;
Heise et al., 1997), and it is being tested in Phase I
clinical trials.
Both of these selective replication-enablement ap-
proaches discussed above were developed by exploiting
the biology of the adenoviral E1 proteins. The E1 region
contains two transcriptional units, E1A and E1B, that
each encode multiple proteins (Berk et al., 1979; Esche et
al., 1980; Bos et al., 1981; Smart et al., 1981; Downey et al.,
1984; Virtanen and Pettersson, 1985). One of the E1A
proteins, 289 amino acids in length, is the primary trans
activator that initiates the transcription of multiple viral
genes leading to viral replication (Berk et al., 1979; Esche
et al., 1980; Bos et al., 1981; Carlock and Jones, 1981;
Smart et al., 1981; Downey et al., 1984; Moran et al., 1986;
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Lillie et al., 1987; Schneider et al., 1987; Jelsma et al.,
1988; Lillie and Green, 1989; Liu and Green, 1994). Both
the 289-amino acid and the closely related 243-amino
acid E1A proteins also direct the cell toward apoptosis
by p53-dependent and -independent mechanisms (Pilder
et al., 1984; Subramanian et al., 1984; Virtanen and Pet-
tersson, 1985; White and Stillman, 1987; White et al.,
1988, 1991; Rao et al., 1992; Teodoro et al., 1995). Among
the multiple E1B proteins, the 19- and 55-kDa proteins
derived from the same 2.2-kb E1B transcript have been
shown to function in concert with the E1A 13s product to
initiate viral replication and oppose the apoptotic effects
of the E1A proteins (Bos et al., 1981; Pilder et al., 1984;
Subramanian et al., 1984; Virtanen and Pettersson, 1985;
Bernards et al., 1986; Barker and Berk, 1987; White and
Stillman, 1987; White et al., 1988, 1991; McLorie et al.,
1991; Rao et al., 1992; Teodoro et al., 1995). These ob-
servations form the basis for the development of tech-
niques to replication-enable E1A/B-defective adenovi-
ruses by supplying both E1A and E1B proteins in trans.
With the knowledge that the E1 proteins can replica-
tion-enable in trans, the amplification approach alluded
to above was accomplished by introducing either plas-
mid DNA or RNA transcripts encoding the E1A and E1B
functions required for replication (Dion et al., 1996a,b;
Goldsmith et al., 1994). The selectivity was based on
limiting the delivery of the E1-encoding nucleic acids to
the neoplastic tissue. These initial studies used com-
plete E1A and E1B complementation and did not address
the question of possible differences in E1B requirements
among cell lines differing in p53 phenotype.
The possible importance of the p53 phenotype in tu-
mor cells was highlighted by the cytoreductive strategy
reports utilizing an adenovirus that was only partially
E1-defective as a consequence of a deletion in the E1B
region inactivating the 55 kDa-encoding portion of the
E1B unit. The selectivity in the cytoreductive reports
appeared to correlate with the p53 status of the cell lines
examined, i.e., those cell lines defective in p53 supported
the highest levels of adenoviral replication (Bischoff et
al., 1996; Heise et al., 1997). However, the finding that
some cell lines with normal p53 phenotype also sup-
ported replication of the partially E1B-defective virus sug-
gested that additional host cell factors were also impor-
tant (Heise et al., 1997).
To better define the specific E1B requirements for
replication of E1-defective adenovirus, the experiments
reported here quantified new adenovirus production in a
panel of cell lines infected with an E1-defective adeno-
virus and simultaneously transfected with plasmids en-
coding E1A together with either 19-kDa E1B, bcl-2, or
55-kDa E1B. The cell lines used were all non-small cell
lung cancer and varied in p53 status as well as basal
bcl-2 and IL-6 content. The results showed that differ-
ences in these three host cell variables did not obviate
the requirement for E1A and both E1B components to
achieve maximal adenoviral replication in the trans
complementation experiments employed here. In some,
but not all of the cell lines, bcl-2 appeared to functionally
substitute for the 19-kDa E1B protein.
RESULTS
The E1A and E1B requirements for adenoviral replica-
tion were tested in a panel of non-small cell lung cancer
(NSCLC) cell lines selected primarily on the basis of two
criteria. First, the cell lines were shown to have compa-
rable ‘‘transducibility’’ to both adenoviral infection and
cationic lipid-mediated transfection (see Methods). Sec-
ond, the cell lines had a defined and varied p53 status on
the basis of previous reports (Table 1) (Phelps et al.,
1996). Basal IL-6 production was subsequently mea-
sured in the cell lines because of some earlier reports
suggesting that IL-6 could substitute for E1A in the con-
text of adenoviral replication in some cell lines (Spergel
and Chen-Kiang, 1991; Spergel et al., 1992). Lysates of
the cell lines assayed under growth conditions used for
the following complementation experiments showed a
wide variation in IL-6 levels, ranging from 0.4 to 261
pg/mg protein.
As a further characterization of the cell lines, relative
expression levels of bcl-2 were examined. The rationale
for this assessment was based on prior reports that bcl-2
was a functional homolog of the 19-kDa E1B protein in
the context of opposing the p53-dependent apoptosis.
Western blot analysis showed two of the five cell lines
had detectable levels of bcl-2 under basal conditions
(Fig. 1) with the results included in Table 1.
Separate plasmids containing the adenoviral E1A or
E1B transcriptional units were constructed as the first
step in examining the E1 requirements for replication in
the NSCLC cell lines (Fig. 2A). The inserts of both pUC-
E1A and pUC-E1B retained the native transcriptional
regulatory regions and the entire coding sequences for
the adenovirus serotype 5 E1A and E1B regions. HeLa
cells transfected with the E1A or E1B plasmids synthe-
sized transcripts that hybridized with E1A or E1B probes
and comigrated with similar transcripts from 293 cells on
Northern blots (not shown).
TABLE 1
Cell Line Characteristics
Cell line p53a bcl-2b IL-6c
H1650 wt 2 261
H522 mut 2 0.4
H358 mut 2 9
H1299 mut 1 0.4
H838 wt 1 219
a wt, wild type; mut, mutation.
b 1, detected by Western blot; 2, undetectable by Western blot.
c pg IL-6/mg protein.
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The pUC-E1A and pUC-E1B plasmids were shown to
trans complement E1-defective adenovirus in quantita-
tive adenovirus production assays (Fig. 2B). HeLa cells
were simultaneously infected with adenovirus defective
in both E1A and E1B (AdCMV-luc) and cationic lipid-
complexed plasmid (‘‘cotransduced’’), after which the new
virus was measured by plaque assay in the lysates. This
analysis showed that the E1A plasmid (pUC-E1A) did
significantly increase the virus detected in the lysates
compared to controls that were cotransduced with the
empty plasmid (pUC13) alone. In contrast, the E1B plas-
mid (pUC-E1B) alone did not significantly raise virus
levels compared to the controls. However, the combina-
tion of the E1A and E1B plasmids resulted in a 2 log
increase in new virus detected in the lysate compared to
either plasmid alone. It was concluded from these ex-
periments that both the E1A and E1B plasmids were
required to maximally trans complement the E1-defective
virus in the context of replication.
Analogous complementation assays using cotrans-
duction of the E1 plasmids and E1-defective adenovirus
with the panel of NSCLC cell lines showed results sim-
ilar to those obtained with HeLa (Fig. 3). In all cases,
FIG. 1. Basal bcl-2 expression in NSCLC cell lines. Shown is the
chemiluminscent radiographic image of a Western blot incubated with
the bcl-2 antibody. Cell line origin of the lysates is shown above. Arrow
points to the 26-kDa band that comigrates with the bcl-2 protein
present in the positive control cell line, H209 (Ben-Ezra et al., 1994).
FIG. 2. Characterization of E1 plasmids used in complementation assays. (A) Maps of E1 plasmids. Shown are maps of the E1 sequences present
in the pUC-E1A and pUC-E1B. Adenoviral nucleotide numbers are indicated above, restriction endonuclease sites defining the ends are shown at 59
and 39 ends where E, EcoRI; X, XhoI; B, BamHI. (B) Functional complementation of E1-defective adenovirus by the E1 plasmids. Abscissa: plasmid(s)
transfected into HeLa cells infected with E1-defective adenovirus; ordinate: plaque forming units (PFU) of adenovirus present in HeLa cell lysates
following cotransduction by E1-defective adenovirus and plasmid(s).
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cotransduction of the E1A or E1B plasmid alone resulted
in amounts of virus in the lysates in greater amounts than
detected in the controls receiving only pUC13. However,
the combined administration of the E1A and E1B plas-
mids yielded the maximal amount of new virus produc-
tion in all five of the cell lines examined here. Importantly,
these experiments did not suggest that the cell lines with
the highest levels of basal IL-6 were any less dependent
on the E1A plasmid for maximal replication than those
with the lowest levels.
To evaluate the possibility that amounts of IL-6 ex-
ceeding those present in any of the cell lines under basal
conditions would provide E1A activity in the context of
replication, additional experiments examined the impact
of exogenous IL-6 on adenoviral replication in the H1299
cell line. Dose-response experiments (Fig. 4A) showed
that for all dose ranges, the amount of virus produced in
lysates exposed to E1-defective adenovirus and the E1B
plasmid remained at a relatively constant fraction of that
produced by cells exposed to virus and both plasmids.
Similar results were obtained with the H1650 cell line
(not shown). Additional experiments addressed the pos-
sibility that the E1A-like activity of IL-6 was critically
dependent on the timing of exposure relative to the
cotransduction (Fig. 4B). For these experiments, the high-
est dosage of IL-6 (1000 U) was added at different times
relative to the transduction (refer to Methods). The re-
sults again showed that IL-6 did not increase the amount
of virus produced by cells exposed to virus and the E1B
plasmid alone relative to the controls receiving no IL-6 in
all three exposure conditions. The sum of these experi-
ments suggest that IL-6 does not significantly impact on
the replication of E1-defective adenovirus.
The next series of experiments sought to examine the
relative contributions of the 19- and 55-kDa E1B compo-
nents to the replication-enablement of E1-defective, re-
combinant adenovirus. These experiments differed from
those employed in the preceding section in that the
E1-defective adenovirus was complemented with the
E1A expression plasmid and different combinations of
plasmids encoding the 19- and 55-kDa E1B proteins. In
addition, these experiments also investigated the contri-
bution of a human bcl-2-encoding plasmid to quantitative
adenovirus replication because it is the functional ho-
molog of the 19-kDa E1B. All three plasmids used the
cytomegalovirus promoter/enhancer to constitutively ex-
press the respective proteins.
As a first step, Western blot analysis was used to
demonstrate that all of the cell lines expressed the plas-
mid-directed proteins following cationic lipid-mediated
transfection under conditions identical to those em-
ployed in the complementation assays that followed (Fig.
5). These experiments showed that all of the cell lines
expressed readily detectable amounts of 19- and 55-kDa
E1B proteins following transfection with the correspond-
ing expression plasmids. The amounts of 19- and 55-kDa
proteins were comparable in all of the cell lines except
H522, in which both proteins were expressed in lower
amounts than the other four cell lines. For the bcl-2
plasmid experiments, the H1650 cell line produced very
low amounts of bcl-2 protein that required long expo-
sures for visualization after multiple transfections. In con-
trast, the remaining four cell lines all expressed compa-
rable amounts of the bcl-2 protein.
The complementation experiments using the E1B
component plasmids did show a disparity in the relative
contributions of the E1B components to the replication of
E1-defective adenovirus (Fig. 6). In all five cell lines, the
combination of the E1A plasmid and the 19-kDa E1B
plasmid resulted in amounts of virus that were signifi-
cantly less (P .0.005) than that obtained with E1A and
both 19- plus 55-kDa-encoding plasmids. The combina-
tion of the E1A plasmid and the bcl-2 plasmid yielded
results similar to those obtained with E1A and 19-kDa
plasmids.
The results observed with the combination of the E1A
and 55-kDa plasmids were more varied (Fig. 6). In sep-
arate experiments performed with the same methods in
triplicate, E1A 1 55 kDa yielded 6.7 6 1.7% and 168 6
58% of the E1A 1 19 kDa 1 55 kDa combination for H358
and H1299, respectively. Thus in H1650 and H1299, E1A
with the 55-kDa plasmid was statistically similar (P .
0.05) to the combination of E1A with both E1B component
plasmids. The remaining three lines, however, yielded
significantly lower amounts of virus in the E1A 1 55-kDa
groups compared to the E1A and both component plas-
mids.
Another point of variability concerned the relative con-
tributions of bcl-2 and the 19-kDa E1B protein (Fig. 6). In
H1299, E1A 1 bcl-2 1 55 kDa was not significantly
different from E1A 1 19 kDa 1 55 kDa. Similar findings
were observed in the H1650 cells, but it should be re-
called that this cell line was idiosyncratic in the context
of expressing lower amounts of the bcl-2 protein follow-
ing transfection. The remaining three cell lines all yielded
a statistically significant lower amount of virus when the
bcl-2 plasmid substituted for the 19-kDa plasmid in com-
bination with E1A and 55-kDa plasmids.
DISCUSSION
The primary objective of the experiments reported
here was the delineation of specific E1 components
required for maximal adenoviral replication in a series of
NSCLC cell lines. The rationale for undertaking this study
was based on the growing interest in developing strate-
gies for selectively enabling adenovirus to replicate in
situ as a means of amplifying therapeutic gene transfer
or as a lytic and thereby cytoreductive therapy.
As will be further discussed below, some earlier stud-
ies had suggested that specific host cell factors could
permit replication of viruses that were partially E1-defec-
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tive. The experimental design here utilized a common,
E1-defective adenovirus that was trans complemented
by a variety of E1 expression plasmids. This was a
quantitative study in that adenovirus was measured in
cell lysates of the cotransduced cells at a single time
point (6 days later). Since maximal adenovirus produc-
tion was the primary endpoint, each cell line served as
its own control so that the modest differences in cationic
lipid-mediated transduction efficiency and intrinsic ca-
pacities for supporting adenovirus replication between
cell lines did not impact on this analysis.
As expected, the initial experiments that utilized com-
plete E1A and E1B plasmids for trans complementation
found the highest yields in the groups receiving E1A plus
E1B compared to groups in which either E1A or E1B were
administered. Although several previous reports have iden-
tified E1A-like activities in specific host cells, our results
suggest these factors were not present in sufficient quan-
tities to obviate the need for the E1A plasmid. These E1A-
like factors, in the context of replication-enablement of E1-
defective adenovirus, include the product of the human
papillomavirus type 16 E7 gene product (Phelps et al.,
1988), a factor stimulated by IL-6 (Spergel and Chen-Kiang,
1991; Spergel et al., 1992), a factor that stimulates expres-
sion of the heat shock protein (Imperiale et al., 1984), and a
factor present in murine embryonal stem cells (Imperiale et
al., 1984; La Thangue and Rigby, 1987). Based on these
reports, the levels of IL-6 were measured and found to
FIG. 3. Adenovirus present in lysates of NSCLC cell lines cotransduced with E1-defective adenovirus and E1-containing plasmids. For all cell lines,
abscissa 5 plasmid cotransduced with the AdCMVHSV-tk virus; ordinate 5 plaque forming units per milliliter of lysate as a percentage of that present
in the group receiving both the pUC-E1A and pUC-E1B plasmids. (a) H358; (b) H522; (c) H1650; (d) H838; and (e) H1299.
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vary over a 3 log range among this group of NSCLC
cell lines. However, the differences in IL-6 content did
not appear to correlate with the amount of virus pro-
duced in cells cotransduced with E1-defective virus
and the E1B plasmid. The experiments performed with
exogenous IL-6 also failed to detect E1A-like activity in
the context of adenoviral replication. It seems reason-
able to speculate that the previously reported E1A-like
activity associated with IL-6 may have also been de-
pendent on other, undefined host cell factors in the
limited number of cell lines examined.
A second host factor investigated in these experiments
concerned the possible influence of p53 status on the
requirement for specific E1B components in our trans
complementation system. Unlike most earlier studies that
compared different defective viruses, the present comple-
mentation system utilized a common E1-defective adenovi-
rus so that the observed replication differences between
groups are due to the complementation differences.
The role of the 55-kDa E1B protein in adenoviral rep-
lication in p53-defective cells has been extensively stud-
ied. It is widely accepted that one of the functions of the
FIG. 4. Effects of exogenous IL-6 on adenovirus replication. (A) Dose-response curve. IL-6 was added to cells immediately following the 4-h
cotransduction with E1-defective virus and plasmid(s) indicated by the legend above. Abscissa: dose of IL-6; ordinate: plaque forming units per
milliliter of lysate as a percentage of that present in the group receiving both the pUC-E1A and pUC-E1B plasmids. (B) Time dependency of IL-6
exposure on adenovirus replication. IL-6 (1000 U/ml) was added approximately 24 h before cotransduction, immediately following cotransduction (‘‘at
cotransduction’’), or approximately 24 h post-cotransduction. Abscissa: time of IL-6 addition relative to cotransduction; ordinate: same as in (A).
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55-kDa E1B protein is the inhibition of E1A-induced ap-
optosis primarily by directly binding to p53 (Kao et al.,
1990; Sarnow et al., 1982a; Yew et al., 1990; Yew and
Berk, 1992, 1994; Teodoro et al., 1994, 1995). It was the
E1B–p53 interaction that formed the rationale for the
studies by Bischoff et al. (1996), who reported a virus
defective in the 55-kDa E1B protein, dl1520, replicated
primarily in p53-defective cells. A second report using
the same virus in a larger panel of cell lines observed
efficient replication in 7/10 cell lines with intact p53
(Heise et al., 1997).
The 55-kDa E1B is also an important mediator of late
viral gene expression and mRNA accumulation (Babies
and Ginsberg, 1984, 1985; Pilder et al., 1986; Yew et al.,
1990), and at least some of this function is dependent on
the formation of a complex with the E4orf6 protein
(Bridge and Ketner, 1990; Goodrum et al., 1996; Pilder et
al., 1986; Rubenwolf et al., 1997). These additional 55-
kDa E1B functions suggest that viruses defective for this
protein may not be optimally productive in cells indepen-
dent of the p53 status. Our findings presented here were
in agreement with this expectation, since all cell lines
required the 55-kDa product for maximal virus pro-
duction.
It has been previously reported that bcl-2 is commonly
elevated in non-small cell lung cancer (Fontanini et al.,
1993; Pezzella et al., 1993; Ritter et al., 1995; Kitagawa et
al., 1996). Prior work has demonstrated that the E1B
19-kDa protein has functional similarities with bcl-2 (Rao
et al., 1992; Chiou et al., 1994; Shen and Shenk, 1994)
with regions homologous to bcl-2 homology (BH) regions
1 and 3 (Han et al., 1995; Subramanian et al., 1995), as
well as playing a role in counteracting the TNF response
to adenoviral infection (White et al., 1992). Based on
these findings, it seemed reasonable to hypothesize that
lung cancer cell lines overexpressing bcl-2 and with a
mutant p53 might efficiently support the replication of
adenovirus complemented with E1A 1 55-kDa E1B-en-
coding plasmid compared to the group complemented
with E1A 1 19-kDa 1 55-kDa-encoding plasmids. How-
ever, our results appeared to dispute hypothesis. In the
one bcl-2-positive cell line (H838) in which this direct
comparison was made, the E1A 1 55-kDa group pro-
duced a statistically significant lower amount of virus
compared to the E1A 1 19-kDa 1 55-kDa group.
Since basal expression of bcl-2 may have been too
low in these particular cell lines to substitute for the
19-kDa E1B function in these cell lines, a bcl-2 expres-
sion plasmid was used in the complementation assays
in lieu of the 19-kDa E1B expression plasmid. These
experiments yielded variable results. In two of the lines,
H1650 and H1299, the bcl-2 plasmid functionally substi-
tuted for the 19-kDa E1B plasmid as evidenced by the
fact that quantities of virus produced in the two groups
(E1A 1 19K 1 55K vs E1A 1 bcl-2 1 55K) were not
significantly different. In the remaining lines, the group
receiving E1A 1 19-kDa 1 55-kDa plasmids yielded
significantly higher levels of virus compared to the E1A
1 bcl-2 1 55-kDa group. It is important to note that all
three plasmids (19 kDa, 55 kDa, bcl-2) utilized a common
transcriptional regulator so that these differences were
not the consequence of differential promoter utilization
between cell lines. It seems reasonable to speculate that
analogous to the relationship of 55-kDa E1B and p53,
multiple host cell factors may interact with bcl-2 in ways
that modulate its ability to functionally substitute for the
19-kDa E1B protein.
FIG. 5. Western blot analysis of E1B component and bcl-2 expression
in cell lines following transfection of expression plasmids. (A) 19-kDa
E1B: shown is the chemiluminescent image of Western blots of lysates
from the cell lines identified above before (2) and after (1) cationic
lipid-mediated transfection of the pCMV-19K plasmid. Primary anti-
body 5 19C-1. Arrow defines the dominant band present after trans-
fection that comigrates with the 19-kDa protein present in lysates from
cells (HeLa) infected with the wild-type adenovirus, wt 300. (B) 55-kDa
E1B: same as in (A) following transfection with the pCMV-55K plasmid.
Primary antibody 5 2A6. Arrow defines the dominant band present
after transfection that comigrates with the 55-kDa protein present in
lysates from cells infected with wt 300. (C) bcl-2: Same as in (A)
following transfection with the pRc-CMV/hBcl-2 plasmid. Only post-
transfection lysates were used here. Primary antibody same as that
used for Fig. 1. Arrow defines the dominant band present after trans-
fection that comigrates with the bcl-2 protein present in H209.
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In conclusion, the results presented here did not dem-
onstrate that IL-6 could functionally substitute for E1A in
the context of adenoviral replication. Furthermore, the
data presented here strongly suggests that multiple host
cell factors modulate the requirements for specific E1
components supplied in trans for the replication-enable-
ment of E1-defective adenovirus. Although there is grow-
ing interest in the development of replicating virus sys-
tems based on E1 complementation strategies, it seems
unlikely that p53 or bcl-2 status will always predict the
ability of the target cells to efficiently support replication
in the context of partial E1B complementation.
METHODS
Cell lines and tissue culture
All cell lines obtained directly from the American Type
Culture Collection (ATCC, Rockville, MD) were all grown
in DMEM/F12 medium supplemented with 10% fetal calf
serum and 2 mM glutamine (‘‘normal media’’) in a water-
FIG. 6. Relative contributions of the E1B component proteins to the replication of E1-defective recombinant adenovirus in NSCLC cell lines.
Adenovirus was quantified in the lysates of the cell line identified in the legend above each graph following cotransduction with AdCMVHSV-tk and
the E1 plasmid(s) identified on the abscissa. Amount of virus recovered 6 days later is expressed as the percentage of that recovered from the cells
cotransduced with E1A, 19-kDa E1B, and 55-kDa E1B expression plasmids. pUC, pUC13; E1A, pUC-E1A; bcl, pRc-CMV/hBcl-2; 19, pCMV-19K; and 55,
pCMV-55K. Results are the mean of three separate experiments for each cell line 6 SEM. Significance of difference between each group and
‘‘E1A/19/55’’ was determined by two-tailed t test. In groups without a designated P value above the bar, P , 0.0001. (a) H358; (b) H522; (c) H1650; (d)
H838; and (e) H1299.
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saturated, 5% CO2 atmosphere at 37°C. All cell lines
were passaged without any antibiotics and were proven
mycoplasma negative by regular testing by Hoechst
staining.
Adenovirus, plasmids, and probes
The E1-defective adenovirus, AdCMV-luc, containing a
cytomegalovirus-directed luciferase-encoding sequence
within the deleted E1 site that eliminated all E1A and E1B
function, was provided by R. Gerard (Center for Trans-
gene Technology and Gene Therapy, Leuven, Belgium).
The E1-defective adenovirus, AdCMV HSV-TK (Rosenfeld
et al., 1995), was provided by D. Curiel (University of
Alabama at Birmingham, Birmingham, AL). This virus
was identical to the AdCMV-luc except that the luciferase
expression cassette was replaced by a CMV-directed
herpes simplex virus thymidine kinase expression cas-
sette within the deleted E1 site. The AdCMV HSV-TK
virus was used for all of the experiments with the non-
small cell lung cancer (NSCLC) cell lines. The viruses
were amplified, titered, and stored as previously de-
scribed (Goldsmith et al., 1994; Dion et al., 1996b). The
AdCMV lacZ virus, containing a CMV-directed bacterial
lacZ gene, was provided by J. Wilson (University of Penn-
sylvania, Philadelphia, PA).
Two plasmids were made to express the E1A or E1B
proteins, respectively, under control of the native adeno-
viral transcriptional regulatory elements. The E1A plas-
mid, pUC-E1A, was constructed by amplifying the E1A
region from wild-type adenovirus serotype 5, WT 300
(Pilder et al., 1984) by the polymerase chain reaction
(PCR). WT 300 DNA was prepared as previously de-
scribed (Goldsmith et al., 1994) and incubated with prim-
ers designed to amplify the region defined by adenovirus
nucleotides 30–1645 with the addition of EcoRI and XhoI
restriction endonuclease sites to the 59 and 39 ends,
respectively, of the amplified fragment. The E1A PCR
fragment was digested with EcoRI and XhoI and ligated
into the same sites of pUC13. Identity was confirmed by
restriction endonuclease mapping, and Northern blot
analysis of cells transfected with the pUC-E1A produced
transcripts that hybridized to an E1A probe and comi-
grated with similarly sized fragments from 293 cells (not
shown). The pUC-E1B plasmid was made as previously
described (Dion et al., 1996b). Northern blot analysis of
cells transfected with pUC-E1B produced transcripts that
hybridized to an E1B probe and comigrated with similarly
sized fragments from 293 cells (not shown).
Plasmids expressing the 19- and 55-kDa E1B proteins
under control of the CMV promoter, pCMV-19K (White
and Cipriani, 1990) and pCMV-55K (White and Cipriani,
1990), respectively, were provided by E. White (Rutgers
University, Piscataway, NJ). The plasmid expressing the
full-length human bcl-2, pRc-CMV/hBcl-2, contained a
full-length human bcl-2 cDNA under transcriptional con-
trol of the CMV promoter/enhancer.
Cotransduction of NSCLC cell lines with E1-defective
adenovirus and E1 plasmids
The relative contribution of the different E1 compo-
nents to replication-enablement of the E1-defective ade-
novirus was assessed by simultaneously exposing the
cell lines to free adenovirus and cationic lipid-complexed
E1 plasmid, a process that is referred to as ‘‘cotransduc-
tion’’ throughout the text.
The cationic lipid was a 50/50% (w/w) mixture of 1,2
dioleoyl-3-trimethylammmonium-propane and L-a-dio-
leoyl phosphatidylethanolamine (Avanti Polar Lipids,
Alabaster, AL) (DOTAP/DOPE) in a lipid:DNA ratio of
2:1 in OptiMEM (Life Technologies, Gaithersburg, MD).
The amount of plasmid and lipid:DNA ratios were
based on preliminary optimization studies using a
luciferase expression plasmid. Using the optimized
conditions, the fraction of cells transduced was deter-
mined by fluorescently activated cell sorter (FACS)
analysis of cells transduced with the lacZ expression
plasmid (0.5 mg/well), pCMVb (Clontech Laboratories,
Inc., Palo Alto, CA) complexed to DOTAP/DOPE. The
conditions for transduction were identical to those
used for all transductions of the E1 plasmids de-
scribed in the following paragraph, and the methods
for FACS analysis of lacZ-positive cells was exactly as
previously described (Rosenfeld et al., 1997). Triplicate
determinations showed the efficiency of DOTAP/DOPE
transduction as follows (mean 6 SEM): H358, 99 6 0%;
H522, 10 6 3%; H838, 93 6 4%; H1299, 95 6 5%;
H1650, 56 6 17%. Similarly, the adenovirus transduc-
tion efficiency was quantified by FACS analysis using
the AdCMV lacZ virus at a multiplicity of infection
(m.o.i.) 5 1. Triplicate determinations showed the effi-
ciency of adenovirus transduction as follows (mean 6
SEM): H358, 58 6 20%; H522, 70 6 15%; H838, 86 6
11%; H1299, 84 6 16%; H1650, 80 6 16%.
Cells were seeded in 24-well plates at a density of
5 3 104 cells/well 18–20 h prior to cotransduction; 6
wells were used for each group. At the time of cotrans-
duction, media was aspirated and replaced with 250
ml of OptiMEM containing AdCMV HSV-TK (m.o.i. 5 1)
and the DNA complexes (0.5 mg DNA/well of 24-well
plate). The contents of each well were aspirated after
4 h at 37°C and replaced with 0.5 ml of normal media
for 6 days. Lysates for virus quantification were pre-
pared by replacing the media from each well with 250
ml of fresh normal media, followed by three freeze/
thaw cycles. Lysates were clarified by centrifugation
and stored at 270°C until quantification of virus
present by 293 cell plaque assay as previously de-
scribed (Dion et al., 1996b).
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Western blot analyses
Basal bcl-2 content was assessed in cell lysates by
Western blot analysis. Lysates were prepared from the
cell lines at the point of reaching confluence under nor-
mal growth conditions without any stimulation. The cell
lysis method and determination of protein was as previ-
ously described (Dion et al., 1997). The proteins were
size fractionated (20 mg/lane) in parallel with protein
markers (low-range markers; BioRad, Hercules, CA) un-
der denaturing conditions in a 12% sodium dodecyl sul-
fate-polyacrylamide gel; transfer and identification of
protein markers was as previously described (Dion et al.,
1997). The bcl-2 protein was identified on the membrane
by incubation with a 1:1000 dilution of clone 124 mono-
clonal antibody (Pezzella et al., 1990) (Dako Corp.,
Carpinteria, CA) followed by chemiluminescent visualiza-
tion of the bound secondary antibody using the reagents
and instructions of a kit (ECL Western blotting Analysis
System, Amersham Corp., Arlington Heights, IL). Expres-
sion of bcl-2 in the cell lines following transfection of
pRcCMV-hBcl-2, provided by J. Reed (Burnham Institute,
La Jolla, CA), used the same transfection conditions as
the complementation assays with the same plasmid, and
the same Western blot analysis methods as for the as-
sessment of basal bcl-2 expression.
Expression of the 19- and 55-kDa E1B proteins follow-
ing transfection of the plasmids pCMV-19K and pCMV-
55K were similarly assessed. In these experiments, the
cell lines were transfected under the same conditions
used for the complementation assays and lysates exam-
ined using the methods described for the bcl-2 Western
blot analyses. The primary antibody for the 19-kDa pro-
tein was 19C-1 provided by P. Branton (McGill University,
Montreal) (McGlade et al., 1987) at a dilution of 1:5000.
The primary antibody for the 55-kDa protein was 2A6
provided by A. Levine (Princeton University, Princeton,
NJ) (Sarnow et al., 1982b) at a dilution of 1:400.
Interleukin-6 analyses
IL-6 content in cell lysates was quantified by enzyme
linked immunoassay (ELISA). Lysates were prepared
from the cell lines under growth conditions identical to
those at the start of the cotransduction assays. The
ELISA was performed with the reagents and exactly
according to the instructions of a kit (Quantikine HS
human IL-6 immunoassay, R & D Systems, Minneapolis,
MN). Each sample was measured in quadruplicate in
two separate assays. All values reported were obtained
within the linear range defined by the standards. Total
protein of each lysate was measured as for the Western
blot analysis.
Additional experiments examined the effects of virus
production by exposing H1299 cells to exogenous IL-6.
Dose-response studies added IL-6 (Collaborative Bio-
medical Products, Bedford, MA) at the time of media
change following the 4 h incubation of the AdCMV
HSV-TK and E1 plasmids in progressive amounts defined
in the text. The media was not changed until time of
lysate harvest 72 h after cotransduction. The possible
effects of varying the sequence of IL-6 exposure relative
to the time of cotransduction were examined by adding
1000 U IL-6 (i) 20–24 h prior to cotransduction, (ii) imme-
diately following cotransduction as in the dose response
studies, or (iii) 20–24 h after cotransduction. All lysates
were harvested 72 h after cotransduction.
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